45 related articles for article (PubMed ID: 28554190)
1. "The Google of Healthcare": enabling the privatization of genetic bio/databanking.
Spector-Bagdady K
Ann Epidemiol; 2016 Jul; 26(7):515-519. PubMed ID: 27449572
[TBL] [Abstract][Full Text] [Related]
2. The Dynamic and Multifaceted Nature of Cardiovascular Disease and Using Genetic Testing to Inform Clinical Care: An International Perspective.
Baudhuin LM; De Backer J; Ingles J; Milewicz DM; Tybjaerg-Hansen A
Clin Chem; 2021 Jan; 67(1):33-40. PubMed ID: 33257948
[No Abstract] [Full Text] [Related]
3. Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe.
Lu M; Lewis CM; Traylor M
BMC Med Genomics; 2017 Jun; 10(1):47. PubMed ID: 28629370
[TBL] [Abstract][Full Text] [Related]
4. 23andMe resumes giving consumers genetic health information: Company's tests for rare and common diseases aren't diagnostic.
Am J Med Genet A; 2017 Aug; 173(8):2003-2004. PubMed ID: 28703454
[No Abstract] [Full Text] [Related]
5. Genetics of Depression: Progress at Last.
Mullins N; Lewis CM
Curr Psychiatry Rep; 2017 Aug; 19(8):43. PubMed ID: 28608123
[TBL] [Abstract][Full Text] [Related]
6. The rise and fall and rise again of 23andMe.
Check Hayden E
Nature; 2017 Oct; 550(7675):174-177. PubMed ID: 29022933
[No Abstract] [Full Text] [Related]
7. Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma.
Wrzeszczynski KO; Frank MO; Koyama T; Rhrissorrakrai K; Robine N; Utro F; Emde AK; Chen BJ; Arora K; Shah M; Vacic V; Norel R; Bilal E; Bergmann EA; Moore Vogel JL; Bruce JN; Lassman AB; Canoll P; Grommes C; Harvey S; Parida L; Michelini VV; Zody MC; Jobanputra V; Royyuru AK; Darnell RB
Neurol Genet; 2017 Aug; 3(4):e164. PubMed ID: 28740869
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide meta-analysis of cognitive empathy: heritability, and correlates with sex, neuropsychiatric conditions and cognition.
Warrier V; Grasby KL; Uzefovsky F; Toro R; Smith P; Chakrabarti B; Khadake J; Mawbey-Adamson E; Litterman N; Hottenga JJ; Lubke G; Boomsma DI; Martin NG; Hatemi PK; Medland SE; Hinds DA; Bourgeron T; Baron-Cohen S
Mol Psychiatry; 2018 Jun; 23(6):1402-1409. PubMed ID: 28584286
[TBL] [Abstract][Full Text] [Related]
9. Direct-to-consumer genetic testing with third party interpretation: beware of spurious results.
Horton R; Crawford G; Freeman L; Fenwick A; Lucassen A
Emerg Top Life Sci; 2019 Nov; 3(6):669-674. PubMed ID: 32915220
[TBL] [Abstract][Full Text] [Related]
10. Third party interpretation of raw genetic data: an ethical exploration.
Badalato L; Kalokairinou L; Borry P
Eur J Hum Genet; 2017 Nov; 25(11):1189-1194. PubMed ID: 28832567
[TBL] [Abstract][Full Text] [Related]
11. Attitudes and interest in incorporating BRCA1/2 cancer susceptibility testing into reproductive carrier screening for Ashkenazi Jewish men and women.
Hardy MW; Peshkin BN; Rose E; Ladd MK; Binion S; Tynan M; McBride CM; Grinzaid KA; Schwartz MD
J Community Genet; 2022 Jun; 13(3):281-292. PubMed ID: 35486291
[TBL] [Abstract][Full Text] [Related]
12. Physician-guided, hybrid genetic testing exerts promising effects on health-related behavior without compromising quality of life.
Schricker S; Monje DC; Dippon J; Kimmel M; Alscher MD; Schanz M
Sci Rep; 2021 Apr; 11(1):8494. PubMed ID: 33875689
[TBL] [Abstract][Full Text] [Related]
13. Choices, attitudes, and experiences of genetic screening in Latino/a and Ashkenazi Jewish individuals.
Reed-Weston AE; Espinal A; Hasar B; Chiuzan C; Lazarin G; Weng C; Appelbaum PS; Chung WK; Wynn J
J Community Genet; 2020 Oct; 11(4):391-403. PubMed ID: 32382939
[TBL] [Abstract][Full Text] [Related]
14. Cases in Precision Medicine: When Patients Present With Direct-to-Consumer Genetic Test Results.
Artin MG; Stiles D; Kiryluk K; Chung WK
Ann Intern Med; 2019 May; 170(9):643-650. PubMed ID: 31035287
[TBL] [Abstract][Full Text] [Related]
15. Consumer genomics will change your life, whether you get tested or not.
Khan R; Mittelman D
Genome Biol; 2018 Aug; 19(1):120. PubMed ID: 30124172
[TBL] [Abstract][Full Text] [Related]
16. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care.
Tandy-Connor S; Guiltinan J; Krempely K; LaDuca H; Reineke P; Gutierrez S; Gray P; Tippin Davis B
Genet Med; 2018 Dec; 20(12):1515-1521. PubMed ID: 29565420
[TBL] [Abstract][Full Text] [Related]
17. 23andMe Paves the Way for Direct-to-Consumer Genetic Health Risk Tests of Limited Clinical Utility.
Wynn J; Chung WK
Ann Intern Med; 2017 Jul; 167(2):125-126. PubMed ID: 28554190
[No Abstract] [Full Text] [Related]
18. Direct-to-consumer genetic testing: Perspectives on its value in healthcare.
Delaney SK; Christman MF
Clin Pharmacol Ther; 2016 Feb; 99(2):146-8. PubMed ID: 26517013
[TBL] [Abstract][Full Text] [Related]
19. 23andMe: a new two-sided data-banking market model.
Stoeklé HC; Mamzer-Bruneel MF; Vogt G; Hervé C
BMC Med Ethics; 2016 Mar; 17():19. PubMed ID: 27059184
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
